GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

April 25, 2017 updated by: Novo Nordisk A/S
This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100004
        • Novo Nordisk Investigational Site
  • France
      • Paris La défense cedex, France, 92932
        • Novo Nordisk Investigational Site
  • Germany
      • Mainz, Germany, 55127
        • Novo Nordisk Investigational Site
  • India
      • Bangalore, India, 560001
        • Novo Nordisk Investigational Site
  • Japan
      • Tokyo, Japan, 1000005
        • Novo Nordisk Investigational Site
  • Russian Federation
      • Moscow, Russian Federation, 119330
        • Novo Nordisk Investigational Site
  • Spain
      • Madrid, Spain, 28033
        • Novo Nordisk Investigational Site
  • Turkey
      • Istanbul, Turkey, 34335
        • Novo Nordisk Investigational Site
  • United Kingdom
      • Crawley, United Kingdom, RH11 9RT
        • Novo Nordisk Investigational Site
  • United States
    • New Jersey
      • Princeton, New Jersey, United States, 08540
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Insulin treated patients with diabetes (type 1 or 2), and physicians involved in the treatment, management of diabetes and care of patients with diabetes.

Description

Inclusion Criteria:

  • PATIENTS WITH DIABETES:
  • Age 18 years or older
  • Treated with insulin
  • Type 1 or Type 2 diabetes
  • PHYSICIANS:
  • In practice for more than 1 year since completing residency
  • See a minimum number of patients with diabetes per week (primary care physicians 5, specialists 10)
  • Initiate insulin treatment for patients with diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Ecologic or Community
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with diabetes
Behavioral: No treatment given
Survey conducted through computer-assisted telephone interviewing.
Physicians
Behavioral: survey
Survey conducted via the Internet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Frequency of insulin omission/non-adherence
Time Frame: In the past 30 days prior to the day when responding to the survey (patient survey)
In the past 30 days prior to the day when responding to the survey (patient survey)
Reasons for insulin omission/non-adherence reported by patient and physician
Time Frame: Day 1 (when responding to the survey)
Day 1 (when responding to the survey)

Secondary Outcome Measures

Outcome Measure
Time Frame
Impact of insulin treatment on life domains (patient survey)
Time Frame: Day 1 (when responding to the online questionnaire)
Day 1 (when responding to the online questionnaire)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (Actual)

September 1, 2010

Study Completion (Actual)

September 1, 2010

Study Registration Dates

First Submitted

September 23, 2013

First Submitted That Met QC Criteria

September 23, 2013

First Posted (Estimate)

September 25, 2013

Study Record Updates

Last Update Posted (Actual)

April 27, 2017

Last Update Submitted That Met QC Criteria

April 25, 2017

Last Verified

April 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GAPP1
  • U1111-1136-2507 (Other Identifier: WHO)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on No treatment given

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe